ImmunOs Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ImmunOs Therapeutics's estimated annual revenue is currently $5.9M per year.
- ImmunOs Therapeutics's estimated revenue per employee is $155,000
Employee Data
- ImmunOs Therapeutics has 38 Employees.
- ImmunOs Therapeutics grew their employee count by 9% last year.
ImmunOs Therapeutics's People
| Name | Title | Email/Phone |
|---|
ImmunOs Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ImmunOs Therapeutics?
Immunos Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This industry leading portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors and exhibit strong anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB).
keywords:N/A
N/A
Total Funding
38
Number of Employees
$5.9M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Schlieren
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 43 | 26% | N/A |
#2 | $5.1M | 44 | -19% | N/A |
#3 | $7M | 45 | 29% | N/A |
#4 | $5.6M | 48 | 4% | N/A |
#5 | $10.9M | 55 | 41% | N/A |